Avalon GloboCare CEO David Jin, M.D., Ph.D. to Chair and Speak at the Plenary Session of the 14th Annual World Stem Cell Summit
Plenary Session and Presentation entitled "Status of Cellular Therapy and Regenerative Medicine in China"
FREEHOLD, N.J., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, announced today that its President and Chief Executive Officer, David Jin, M.D., Ph.D., will chair and speak at the plenary session of the 14th Annual World Stem Cell Summit in Miami, Florida. The presentation is entitled, "Status of Cellular Therapy and Regenerative Medicine in China."
|Date:||January 24, 2019|
|Time:||9:20 a.m. ET|
|Venue:||Hyatt Regency Miami|
"Avalon GloboCare is dedicated to assembling and integrating the premier scientific, clinical, and regulatory resources from around the world, in order to accelerate innovative and transformative cellular technologies and their clinical applications," stated Dr. David Jin. "We are honored to lead a panel with leading experts from the U.S. and China to discuss an evolving ecosystem of cellular therapy and regenerative medicine. We look forward to sharing our experiences and capabilities in cell-based technologies and therapeutics," added Dr. Jin.
The 2019 World Stem Cell Summit is the global, super-ecosystem event, trans-disciplinary in scope. The Summit is designed to breakdown silos, expand scientific/clinical knowledge and forge collaborations, with the overarching collective goal to improve health and deliver cures. For more information please visit: http://www.worldstemcellsummit.com
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to advancing cell-based technologies and therapeutics, with a focus on developing and empowering innovative and transformative cell-based technologies and their clinical applications. In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics, cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.
About the World Stem Cell Summit
Produced by the 501(c)(3) non-profit Regenerative Medicine Foundation (RMF), and in its 14th year, the World Stem Cell Summit 2019 is co-located with the Phacilitate Leaders World 2019. It is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science, cellular therapy and regenerative medicine field. With the overarching purpose of fostering biomedical research, funding, and investments targeting cures, the Summit is the single conference serving the diverse ecosystem of stakeholders.
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
Crescendo Communications, LLC
Tel: (212) 671-1020
Released January 15, 2019